About Rdmd
Rdmd: Unlocking New Treatments for Rare Diseases
Rdmd, formerly known as AllStripes, is a Public Benefit Corporation that is dedicated to unlocking new treatments for people affected by rare diseases. The company was founded in 2018 by Dr. Ethan Perlstein and Dr. Alex Sherman, who both have extensive experience in the field of rare disease research.
Rare diseases are defined as conditions that affect fewer than 200,000 people in the United States. Despite their rarity, there are over 7,000 different types of rare diseases that collectively affect an estimated 400 million people worldwide. Many of these conditions are genetic and can be life-threatening or severely debilitating.
One of the biggest challenges facing patients with rare diseases is the lack of effective treatments. Because these conditions are so uncommon, there is often little research into their underlying causes and potential therapies. This means that patients may go years without a diagnosis or effective treatment options.
Rdmd aims to change this by leveraging technology to accelerate rare disease research and drug development. The company has developed a platform called MyRARE™ that allows patients with rare diseases to share their medical data securely and anonymously with researchers around the world.
By aggregating this data from thousands of patients across hundreds of different rare diseases, Rdmd hopes to identify commonalities between these conditions and develop new therapies based on shared biological pathways or genetic mutations.
In addition to its patient-centric approach to research, Rdmd also partners with pharmaceutical companies and academic institutions to advance drug development programs for specific rare diseases. By combining its unique patient data resources with cutting-edge scientific expertise, Rdmd aims to bring new treatments to market faster than ever before.
One example of Rdmd's success in this area is its partnership with Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing therapies for serious ultra-rare genetic disorders. Together, Rdmd and Ultragenyx have launched a natural history study of patients with six different rare diseases, which will help inform the design of future clinical trials and accelerate the development of new treatments.
Rdmd's commitment to patient-centered research and collaboration has earned it recognition from both the scientific community and the business world. In 2020, the company was named one of Fast Company's Most Innovative Companies in Biotech, and it has also received funding from prominent venture capital firms such as Spark Capital and Lux Capital.
Overall, Rdmd is a pioneering company that is using technology to transform rare disease research and drug development. By empowering patients to share their data and collaborating with industry leaders, Rdmd is making significant strides towards unlocking new treatments for people affected by rare diseases.